AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Omnicell, Inc. (OMCL) delivered a strong first quarter, crushing Wall Street expectations as the healthcare technology provider reported non-GAAP earnings of $0.55 per share, well above the $0.33 consensus estimate. The Mountain View, California-based company, which provides medication management and supply chain solutions to hospitals and healthcare facilities, posted revenue of $309.9M for the quarter, marking a 15.0% increase from the $269.7M recorded in Q1 2025. Net income reached $11.4M as the company continued to benefit from healthcare providers’ investments in automation and workflow optimization.
The quarter’s performance reflects sustained demand for Omnicell’s automated dispensing systems and analytics platforms, which help hospitals reduce medication errors and streamline pharmacy operations. The double-digit revenue growth underscores the company’s ability to capture market share in an industry increasingly focused on patient safety and operational efficiency.
For Q2 2026, management projected revenue between $307.0M and $313.0M, with non-GAAP earnings per share expected in the $0.40 to $0.48 range. The company also provided full-year 2026 EPS guidance in the same $0.40 to $0.48 range. Wall Street maintains a bullish stance on the stock, with analyst consensus showing 9 buy ratings, 2 hold ratings, and 0 sell ratings.
A detailed analysis of Omnicell, Inc.’s quarter follows shortly on AlphaStreet.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.